中國投資開發(00204.HK)延遲刊發中期業績 2日起停牌
格隆匯12月2日丨中國投資開發(00204.HK)公佈,根據上市規則第13.49(6)條,公司須就其截至2019年9月30日止6個月(“該期間”)的業績(“2019年中期業績”)刊登公告的期限是該期間之後兩個月內,即在2019年11月30日或之前。
公司董事會謹此通知公司股東,公司無法在2019年11月30日之前發佈2019年中期業績,因為公司無法取得一些投資項目公司的資料以編制2019年中期業績。由於相關事項需要更多時間處理,因此董事會會議將會進一步延遲。
公司股份自12月2日起停牌,以待刊發2019年中期業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.